

5741-01-EJF

Application No. 09/284,858

Please replace all prior claims in the application with the following:

Claim 1 (currently amended): A solid pharmaceutical dosage form ~~suitable for~~
~~oral delivery~~ comprising a solid particulate dispersion of a pharmaceutical agent in a
matrix, the pharmaceutical agent being sparingly water-soluble and comprising crystalline
particles dispersed in the matrix to enhance the dissolution rate of the pharmaceutical
agent in water, the matrix directly contacting the pharmaceutical agent and consisting of a
water-soluble polymer, wherein the solid particulate dispersion is made by mixing the
pharmaceutical agent and the polymer at a temperature sufficiently high to melt or soften
the polymer, but insufficiently high to melt the pharmaceutical agent, and wherein the
solid pharmaceutical dosage form is an orally deliverable form.

Claim 2 (currently amended): The A-dosage form of Claim 1 wherein the
pharmaceutical agent is a glitazone.

Claims 3-4 (canceled)

Claim 5 (currently amended): The A-dosage form of Claim 1 wherein the polymer
is hydroxypropyl cellulose.

Claims 6-9 (canceled)

Claim 10 (previously presented): The dosage form of Claim 1 wherein said
dosage form comprises 75 % by weight of said pharmaceutical agent.

Claims 11-20 (canceled)

Claim 21 (currently amended): A solid pharmaceutical dosage form ~~suitable for~~
oral delivery comprising a solid particulate dispersion of a pharmaceutical agent in a
matrix, the pharmaceutical agent being sparingly water-soluble and comprising crystalline
particles dispersed in the matrix to enhance the dissolution rate of the pharmaceutical
agent in water, the matrix directly contacting the pharmaceutical agent and consisting of
at least-one water-soluble polymer, wherein the pharmaceutical agent is a glitazone and

Non-Final Amendment—page 2 of 7

5741-01-EJF

Application No. 09/284,858

the solid particulate dispersion is made by mixing the pharmaceutical agent and the polymer at a temperature sufficiently high to melt or soften the polymer, but insufficiently high to melt the pharmaceutical agent.

Claim 22 (currently amended): The A-dosage form of Claim 21 wherein the polymer is hydroxypropyl cellulose.

Claim 23 (currently amended): The A-dosage form of Claim 21 wherein the pharmaceutical agent and the polymer are present at a weight ratio of 75:25, respectively.

Claim 24 (new): The dosage form of Claim 1, wherein the pharmaceutical agent comprises about 10 % to about 90 % of the solid particulate dispersion by weight.

Claim 25 (new): The dosage form of Claim 1, wherein the pharmaceutical agent comprises about 20 % to about 80 % of the solid particulate dispersion by weight.

Claim 26 (new): The dosage form of Claim 1, wherein the pharmaceutical agent comprises about 40 % to about 80 % of the solid particulate dispersion by weight.

Claim 27 (new): The dosage form of Claim 1, wherein the pharmaceutical agent comprises about 50 % to about 80 % of the solid particulate dispersion by weight.

Non-Final Amendment—page 3 of 7